echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Liu Yong's team at Xiangya Hospital of Central South University and others have discovered a potential mechanism to enhance tumor vaccine response

    Liu Yong's team at Xiangya Hospital of Central South University and others have discovered a potential mechanism to enhance tumor vaccine response

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    This article is the original of Translational Medicine Network, please indicate the source of reprinting

    Written by Mia

    TGF-β signaling is necessary for
    CD8+ T cells to differentiate into tissue-resident memory T cells (TRM).
    Although higher frequencies of CD8+ TRM cells in the tumor microenvironment are associated with a better prognosis, blocking TGF-β generally improves prognosis rather than worsens
    .

    On October 13, 2022, Liu Yong's team at Xiangya Hospital of Central South University and Zhang Nu's team at the University of Texas published a research paper entitled "TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine" in Nature Communications
    。 The study revealed a link between TRM and stem cell-like T cells,which inhibits the migration and effector differentiation of stem cell-like T cells, resulting in weakened
    anti-tumor immunity.

    #Sec1

    Research background

     01 

    Continuous exposure to antigens, such as tumor antigens, can induce T cell exhaustion and reduce effector function
    .
    Depleted CD8+ T cells are heterogeneous, while less depleted subsets have stem-like characteristics
    .
    These stem cell-like CD8+ T cells express the transcription factor TCF-1 (T cytokine-1) and maintain the CD8+ response
    during chronic antigen exposure.
    Importantly, these stem cell-like CD8+ T cells respond to immune checkpoint blockade therapy and are associated
    with the efficacy of oncology vaccines.
    However, the signals that control the maintenance, differentiation, and migration of these stem-like T cells are not fully understood
    .

    Transforming growth factor β (TGF-β) is generally considered an immunosuppressive factor
    .
    Blocking the TGF-β signaling pathway has been shown to promote tumor control
    by targeting tumor stromal compartments or CD4+ T cell-mediated vascular remodeling.
    In addition, systemic blocking of TGF-β synergistically with oncology vaccines or PD-1/PD-L1 blockade promotes CD8+ T cell response
    in mouse models.
    Since most studies on TGF-β on CD8+ T cells do not have knowledge of binding stem-like T cells, it is critical
    to re-examine the role of TGF-β on tumor-specific CD8+ T cells, especially stem cell-like CD8+ T cells.

    Tissue-resident memory T cells (TRM) are a unique population of memory T cells that are separated from blood circulation and maintained
    in a self-sustaining manner.
    TRM was originally discovered in acute infection models and has now been identified as an important component of
    tissue-specific immunity.
    Surprisingly, recent studies have shown that stem cell-like CD8+ T cells produced after chronic viral infection have similar properties to TRM, that is, they are mostly confined to secondary lymphoid organs (such as the spleen and lymph nodes) and non-circulating
    .

    However, it remains unclear whether a similar situation
    exists in the immune oncology environment.
    Most previous studies of tumor-specific CD8+ T cells have focused on tumor-infiltrating lymphocytes (TILs
    ).
    Although cancer immune cycle models are widely accepted, tumor-specific CD8+ T cells in lymphoid organs have largely underappreciated
    .
    TGF-β signaling to CD8+ T cells is known to be critical
    for the differentiation and maintenance of TRM after acute infection.
    In tumor immunity,TRM-like signaling is generally positively correlated
    with the ability of TILs to control tumors.
    TGF-β promotes T RM, TRM limits tumor growth, and TGF-β blockade improves tumor control, but how to fully coordinate this information remains a mystery
    .

    Overview of the study

     02 

    This study demonstrated the role
    of tumor-draining lymph node TDLNs as a reservoir of tumor specific stem cell-like CD8+ T cell residence.
    Using a mouse melanoma model, the researchers found that in tumor-draining lymph nodes (TDLN), rather than in the tumor itself, stem-like CD8+ T cells differentiated into TRMs
    in a TGF-β and tumor antigen-dependent manner.

    In T-cell-specific TGF-β receptor-conditioned knockout mice, CD8+ T cells significantly enhanced their response to tumor vaccines

    After receiving melanoma-specific epitope vaccine, most tumor-specific CD8+ T cells remained in a stem cell-like state, but some cells lost their TRM state, differentiated into CX3CR1+ effector CD8+ T cells in TDLN, and subsequently migrated into tumors
    .
    Disruption of TGF-β signaling alters the dynamics of these developmental processes, ultimately improving the migration
    of effector CD8+ T cells to tumors.

    The results also highlight two unique features of TDLNs in tumor immunotherapy: (1) TDLNs serve as reservoirs for host stem cell-like T cells
    .
    (2) TDLNs as traps
    that limit the migration/differentiation of stem cell-like T cell activity.
    Similar to the tumor environment, the researchers previously demonstrated that TGF-β promotes the retention
    of dry-like CD8+ T cells within lymphfollicles during chronic viral infection.
    Thus, TGF-β-dependent lymphoid tissue-resident procedures are not tumor-specific and may represent a universal feature of
    Tcf-1+CD8+ T cells.

    Summary of the study

     03 

    In summary, TDLN stem cell-like T cells transition from TGF-β-dependent TRM differentiation to the development of anti-tumor migration effector factors after tumor vaccination, and targeted TGF-β blockade can promote this transition
    .

    Resources:

    #Sec1

    Note: This article is intended to introduce the progress of medical research and cannot be used as a reference
    for treatment options.
    If you need health guidance, please go to a regular hospital
    .

    Recommendations, live streams/events

    October 21 14:00-17:30 Shanghai

    Brain nervous system disease diagnosis and drug discovery industry salon

    Scan the QR code to participate for free

    Nov 01-02 09:00-17:30 Chongqing

    The first Southwest Single Cell Omics Technology Application Forum

    Scan the QR code to participate for free

    November 25-27 09:00-17:30 Shanghai

    The 4th Shanghai International Cancer Congress

    Scan the code to participate

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.